Last reviewed 2026-04-23 · How we verify

BL-M07D1

BL-M07D1 is a small molecule drug that targets the molecular target.

BL-M07D1 is a small molecule drug that targets the molecular target. Used for Indication 1.

At a glance

Mechanism of action

The exact mechanism of action of BL-M07D1 is not well understood, but it is believed to work by interacting with the molecular target, leading to a specific therapeutic effect.

Approved indications

• Indication 1

Common side effects

• Adverse event 1

Key clinical trials

• Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors (PHASE1)
• A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC (PHASE2)
• A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy (PHASE3)
• A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer (PHASE3)
• A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC (PHASE3)
• A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma (PHASE3)
• A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer (PHASE2, PHASE3)
• A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.